KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Change in Receivables (2016 - 2025)

Neogenomics (NEO) has disclosed Change in Receivables for 16 consecutive years, with $4.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Receivables rose 573.76% year-over-year to $4.2 million, compared with a TTM value of $6.2 million through Dec 2025, down 68.01%, and an annual FY2025 reading of $6.2 million, down 68.01% over the prior year.
  • Change in Receivables was $4.2 million for Q4 2025 at Neogenomics, up from $2.4 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $9.1 million in Q1 2024 and bottomed at -$3.9 million in Q1 2021.
  • Average Change in Receivables over 5 years is $2.5 million, with a median of $1.5 million recorded in 2022.
  • The sharpest move saw Change in Receivables tumbled 168.52% in 2021, then skyrocketed 1271.46% in 2023.
  • Year by year, Change in Receivables stood at $7.2 million in 2021, then increased by 7.69% to $7.7 million in 2022, then tumbled by 118.3% to -$1.4 million in 2023, then skyrocketed by 37.11% to -$888000.0 in 2024, then soared by 573.76% to $4.2 million in 2025.
  • Business Quant data shows Change in Receivables for NEO at $4.2 million in Q4 2025, $2.4 million in Q3 2025, and -$1.1 million in Q2 2025.